Gardasil | Medicinreferenser

Referenser för Gardasil Författare, artikel och publikation	År	Hämta abstract / fulltext
1. Health and disease. Socialstyrelsen 2005:9	2005
2. Cancer i siffror. Socialstyrelsen 2005	2005
3. Nationellt kvalitetsregister för gynekologisk hälsokontroll. Socialstyrelsen 2004	2004
4. Cain J et al. Preventing cervical cancer. Science 2000:288 :1753-4.	2000
5. Clifford GM, et al. Human papillomavirus types in invasive cervical cancer worldwide; a metanalysis. Br J Cancer 2003;88:63-73.	2003
6. Carter JJ et al. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-9.	2000
7. Cogliano V, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.	2005
8. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999;9:423-30.	1999
9. Ferlay J, et al. GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. IARC CancerBase No. 5 version, 2.2. Lyon: IARC Press; 2004.	2004
10. Ho GY, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 19;338:423-8.	2002
11. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102 (5A):3-8.	1997
12. Koutsky LA, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;357:1645-51.	2002
13. Lowry DR, Howley PM. Fields Virology. In Knipe DM, Howley PM, editors. Papillomaviruses. Philadelphia, USA: Lippincott, Williams and Wilkins; 2001. pp.2231-64.	2001
14. Munoz N, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.	2003
15. Munoz N, et al. HPV in the etiology of human cancer. Vaccine 2006; 24, Suppl 3:S1-10.	2006
16. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol pathol 1993;12:186-92.	1993
17. Pagliusi SR, Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-78.	2004
18. Partridge JM, Koutsky LA. Genital human papillomvirus infection in men. Lancet Infect Dis 2006:6:21-31.	2006
19. Schlecht NF, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003;95:1336-43.	2003
20. Stanley M, et al. prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006;24, Suppl 3: S106-113.	2006

21. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24 Suppl 1:S16-22. Review.	2006
22. Suzich JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papilloma. Proc Natl Acad Sci USA 1995; 92:11553-7.	1995
23. Villa LL, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.	2005
24. Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.	1999

Referenser för Gardasil

Författare, artikel och publikation

År

Hämta abstract / fulltext